Difference between revisions of "Team:UI Indonesia/Safety"

 
(18 intermediate revisions by 5 users not shown)
Line 211: Line 211:
 
.ref{
 
.ref{
 
font-size:18px;
 
font-size:18px;
 +
}
 +
#myBtn {
 +
  display: none;
 +
  position: fixed;
 +
  bottom: 20px;
 +
  right: 30px;
 +
  z-index: 99;
 +
  font-size: 18px;
 +
  border: none;
 +
  outline: none;
 +
  background-color:transparent;
 +
  color: white;
 +
  cursor: pointer;
 +
  padding: 15px;
 +
  border-radius: 4px;
 +
}
 +
 +
#myBtn:hover {
 +
  background-color: #555;
 
}
 
}
 
</style>
 
</style>
  
 
<body>
 
<body>
 +
<button onclick="topFunction()" id="myBtn" title="Go to top"><img src="https://image.flaticon.com/icons/png/512/14/14747.png" style="width:50px;height:50px;"></button>
 +
 
<!-- Navbar -->
 
<!-- Navbar -->
 
<nav class="navbar navbar-default">
 
<nav class="navbar navbar-default">
Line 238: Line 259:
 
         </li>
 
         </li>
 
         <li class="navbar-parts"><a href="https://2018.igem.org/Team:UI_Indonesia/Parts">Parts</a></li>
 
         <li class="navbar-parts"><a href="https://2018.igem.org/Team:UI_Indonesia/Parts">Parts</a></li>
−
<li class="navbar-safety current"><a href="https://2018.igem.org/Team:UI_Indonesia/Safety">Safety</a></li>
+
    <li class="navbar-safety current"><a href="https://2018.igem.org/Team:UI_Indonesia/Safety">Safety</a></li>
−
<li class="dropdown navbar-interlab">
+
    <li class="dropdown navbar-interlab">
 
           <a href="https://2018.igem.org/Team:UI_Indonesia/InterLab">InterLab<span class="caret"></span></a>
 
           <a href="https://2018.igem.org/Team:UI_Indonesia/InterLab">InterLab<span class="caret"></span></a>
 
           <ul class="dropdown-menu">
 
           <ul class="dropdown-menu">
Line 245: Line 266:
 
             <li><a href="https://2018.igem.org/Team:UI_Indonesia/InterLab#materials">Materials and Equipment</a></li>
 
             <li><a href="https://2018.igem.org/Team:UI_Indonesia/InterLab#materials">Materials and Equipment</a></li>
 
             <li><a href="https://2018.igem.org/Team:UI_Indonesia/InterLab#methods">Methods</a></li>
 
             <li><a href="https://2018.igem.org/Team:UI_Indonesia/InterLab#methods">Methods</a></li>
−
<li><a href="https://2018.igem.org/Team:UI_Indonesia/InterLab#results">Results and Discussions</a></li>
+
      <li><a href="https://2018.igem.org/Team:UI_Indonesia/InterLab#results">Results and Discussions</a></li>
−
<li><a href="https://2018.igem.org/Team:UI_Indonesia/InterLab#conclusions">Conclusions</a></li>
+
      <li><a href="https://2018.igem.org/Team:UI_Indonesia/InterLab#conclusions">Conclusions</a></li>
 
           </ul>
 
           </ul>
 
         </li>
 
         </li>
−
<li class="navbar-model"><a href="https://2018.igem.org/Team:UI_Indonesia/Model">Model</a></li>
+
    <li class="navbar-model"><a href="https://2018.igem.org/Team:UI_Indonesia/Model">Model</a></li>
−
<li class="dropdown navbar-humanpractice">
+
    <li class="dropdown navbar-humanpractice">
−
           <a href="https://2018.igem.org/Team:UI_Indonesia/HumanPractices">Human Practices<span class="caret"></span></a>
+
           <a href="https://2018.igem.org/Team:UI_Indonesia/Human_Practices">Human Practices<span class="caret"></span></a>
 
           <ul class="dropdown-menu">
 
           <ul class="dropdown-menu">
−
             <li><a href="https://2018.igem.org/Team:UI_Indonesia/HumanPractices#collapse1">Campus Campaign</a></li>
+
             <li><a href="https://2018.igem.org/Team:UI_Indonesia/Human_Practices">Integrated Human Practice</a></li>
−
             <li><a href="https://2018.igem.org/Team:UI_Indonesia/HumanPractices#collapse2">Social Work</a></li>
+
             <li><a href="https://2018.igem.org/Team:UI_Indonesia/Public_Engagement">Education and Public Engagement</a></li>
−
             <li><a href="https://2018.igem.org/Team:UI_Indonesia/HumanPractices#collapse3">Biosafety & Biosecurity Training</a></li>
+
             <li><a href="https://2018.igem.org/Team:UI_Indonesia/Human_Practices#catalogue">Human Practice Catalogue</a></li>
−
<li><a href="https://2018.igem.org/Team:UI_Indonesia/HumanPractices#collapse4">Human Practice Catalogue</a></li>
+
          </ul>
 +
    </li>
 +
    <li class="navbar-improve"><a href="https://2018.igem.org/Team:UI_Indonesia/Improve">Improve</a></li>
 +
    <li class="navbar-team"><a href="https://2018.igem.org/Team:UI_Indonesia/Team">Team</a></li>
 +
    <li class="navbar-collaborations"><a href="https://2018.igem.org/Team:UI_Indonesia/Collaborations">Collaborations</a></li>
 +
        <li class="dropdown navbar-attributions">
 +
          <a href="https://2018.igem.org/Team:UI_Indonesia/Attributions">Attributions<span class="caret"></span></a>
 +
          <ul class="dropdown-menu">
 +
            <li><a href="https://2018.igem.org/Team:UI_Indonesia/MedalCriteria">Medal Criteria</a></li>
 
           </ul>
 
           </ul>
 
         </li>
 
         </li>
−
<li class="navbar-improve"><a href="https://2018.igem.org/Team:UI_Indonesia/Improve">Improve</a></li>
 
−
<li class="navbar-team"><a href="https://2018.igem.org/Team:UI_Indonesia/Team">Team</a></li>
 
−
<li class="navbar-collaborations"><a href="https://2018.igem.org/Team:UI_Indonesia/Collaborations">Collaborations</a></li>
 
−
<li class="navbar-attributions"><a href="https://2018.igem.org/Team:UI_Indonesia/Attributions">Attributions</a></li>
 
 
       </ul>
 
       </ul>
 
     </div>
 
     </div>
Line 277: Line 302:
  
 
<div class="w3-content w3-container w3-padding-64">
 
<div class="w3-content w3-container w3-padding-64">
−
  <h5> In accordance to the iGEM safety rules, our team used a cellular organism classified in the <i>Risk Group</i> 1. For the purpose of cloning and expression, <i>Escherichia coli</i> K-12-strain derivates were primarily applied in the lab as the main experimental subjects. Standard plasmids with standard antibiotic resistance markers were designed to enhance functions of recombinants selection. To ensure the safety of ourselves and the project, we worked in a BSL-1 (<i>Biosafety type 1</i>) laboratory, following standard safety protocols (e.g. masks, gloves, googles, and protective clothing). The lab also includes the “clean-to-dirty” workflow area, which means that lab staffs do not return to a “clean” area after working in a “dirty” area. For instance, entering PCR room is forbidden after working with DNA isolation or bacterial cultures in DNA room.
+
<h5>In accordance to the iGEM safety rules, our team used organism classified in the Risk Group 1, such as Escherichia coli K-12-strain derivates. To ensure the safety of ourselves and the project, our lab team worked in a BSL-1 (Biosafety Level 1) laboratory, certified internationally by WHO and CEN, in the Institute of Human Virology and Cancer Biology of the Faculty of Medicine, University of Indonesia. The safety criteria of this lab include risk assessment for each project, safety trainings, and standard operational procedures. Several lab administrative strategies are available such as medical surveillance and vaccination for those working with potentially infected human tissues, accident report, and safety drills.</h5> 
 +
<br>
 +
<div align = "center">
 +
<img src = "https://static.igem.org/mediawiki/2018/6/62/T--UI_Indonesia--genlab.png"</img>
 +
</div>
 +
<br>
  
−
  <br><br>
+
<h5> One of our part which raised concern about security is the DiphTox part. The details regarding this part is discussed in <a href ="http://parts.igem.org/Part:BBa_K2607000" style="color:blue">http://parts.igem.org/Part:BBa_K2607000</a> Regarding safety issues, one of the main purposes of the creation of this part is to eliminate the toxic domain of the protein, leaving only the binding domain to be used as test device for HB-EGF/Tar chimeric receptor. In managing the data, our laboratory had applied several safeguards, such as restricted informational access or password-locked computer. We have also discussed this matter with our PI, dr. Budiman Bela, and also with the Lab Biosafety Officer, Mrs. Aroem Naroeni, which also shared the safety aspects of our laboratory.</h5>
−
 
+
 
−
  One of our project’s part which raised concern about biosecurity is the synthetic hand-made <i>Affitoxin</i> (i.e. the binding domain of AB diphtheria exotoxin) design. The details regarding this part would be discussed in <b><a href="http://parts.igem.org/Part:BBa_K2607000" style="color:blue">this page</a></b>. The fact that this part originates from the modification of diphtheria toxin raises concern about safety and security, including the possibilities of dual-use research. Regarding safety issues, the main purpose of the creation of this part is to eliminate the toxic domain of the exotoxin, leaving only the binding domain to be used to test our chimeric HB-EGF/Tar receptor. However, this condition still leaves a security issue regarding dual-use possibilities. Additionally, the creation of this part, if successful, means that we have only isolated the necessary domains needed for binding assays. The full sequence could be used to construct another chimeric protein in which the <i>Affitoxin</i> is linked to a more harmful toxin or material and used to deliver that harmful part into the cytoplasm of human cells containing HB-EGF surface receptor. To handle this, our team are required to comply with rules of iGEM safety committee to be allowed to not publish the full sequence in the iGEM UI 2018 Wiki pages.</h5>
+
<br>
 +
<img src = "https://static.igem.org/mediawiki/2018/8/8d/T--UI_Indonesia--safety1.jpg" width="700"></img>
 +
<h6 align ="center"><b>Figure 1</b>. One of our lab member (<i>Left</i>) interviews Mrs. Aroem (<i>Right</i>) for asking any advices and suggestions regarding team’s project and lab safety.</h5>
 +
<br><br>
 +
 
 +
<h5>As a part of the development of biosafety and biosecurity, iGEM UI team had recently been given the chance to be a speaker in a training conducted by the Indonesian Biorisk Association together with the Federal Bureau Interagency, regarding the potential of dual-use in our project. We planned to consult with the FBI experts about future usage of DiphTox part in this seminar by the end of October 2018.</h5>
 +
 
 +
</h5>
 
</div>
 
</div>
 
   <script src="https://ajax.googleapis.com/ajax/libs/jquery/3.3.1/jquery.min.js"></script>
 
   <script src="https://ajax.googleapis.com/ajax/libs/jquery/3.3.1/jquery.min.js"></script>
 
   <script src="https://maxcdn.bootstrapcdn.com/bootstrap/3.3.7/js/bootstrap.min.js"></script>
 
   <script src="https://maxcdn.bootstrapcdn.com/bootstrap/3.3.7/js/bootstrap.min.js"></script>
 +
<script>
 +
// When the user scrolls down 20px from the top of the document, show the button
 +
window.onscroll = function() {scrollFunction()};
 +
 +
function scrollFunction() {
 +
    if (document.body.scrollTop > 20 || document.documentElement.scrollTop > 20) {
 +
        document.getElementById("myBtn").style.display = "block";
 +
    } else {
 +
        document.getElementById("myBtn").style.display = "none";
 +
    }
 +
}
 +
 +
// When the user clicks on the button, scroll to the top of the document
 +
function topFunction() {
 +
    document.body.scrollTop = 0;
 +
    document.documentElement.scrollTop = 0;
 +
}
 +
</script>
 +
<!-- Footer -->
 +
<footer class="w3-center w3-green w3-padding-64 w3-opacity w3-hover-opacity-off">
 +
  <div class="w3-xlarge w3-section">Team UI Indonesia<br>
 +
    <i class="fa fa-envelope w3-hover-opacity"></i>&ensp; igemui2018@gmail.com
 +
  </div>
 +
</footer>
 +
</body>
 +
</html>

Latest revision as of 03:42, 18 October 2018

SAFETY AND SECURITY ASPECTS
In accordance to the iGEM safety rules, our team used organism classified in the Risk Group 1, such as Escherichia coli K-12-strain derivates. To ensure the safety of ourselves and the project, our lab team worked in a BSL-1 (Biosafety Level 1) laboratory, certified internationally by WHO and CEN, in the Institute of Human Virology and Cancer Biology of the Faculty of Medicine, University of Indonesia. The safety criteria of this lab include risk assessment for each project, safety trainings, and standard operational procedures. Several lab administrative strategies are available such as medical surveillance and vaccination for those working with potentially infected human tissues, accident report, and safety drills.


One of our part which raised concern about security is the DiphTox part. The details regarding this part is discussed in http://parts.igem.org/Part:BBa_K2607000 Regarding safety issues, one of the main purposes of the creation of this part is to eliminate the toxic domain of the protein, leaving only the binding domain to be used as test device for HB-EGF/Tar chimeric receptor. In managing the data, our laboratory had applied several safeguards, such as restricted informational access or password-locked computer. We have also discussed this matter with our PI, dr. Budiman Bela, and also with the Lab Biosafety Officer, Mrs. Aroem Naroeni, which also shared the safety aspects of our laboratory.

Figure 1. One of our lab member (Left) interviews Mrs. Aroem (Right) for asking any advices and suggestions regarding team’s project and lab safety.


As a part of the development of biosafety and biosecurity, iGEM UI team had recently been given the chance to be a speaker in a training conducted by the Indonesian Biorisk Association together with the Federal Bureau Interagency, regarding the potential of dual-use in our project. We planned to consult with the FBI experts about future usage of DiphTox part in this seminar by the end of October 2018.
Team UI Indonesia
  igemui2018@gmail.com